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Markers of bone turnover are becoming an important tool for practitioners in the management 
of osteoporosis. Therefore, it is essential to establish a reference database of the markers before 
using them in various clinical settings.  
A total of 785 individuals (37% males, 63% females) without apparent or suggested 
abnormalities affecting bone mass were randomly selected from 13 clusters in Bushehr Port in 
southern Iran. The serum CrossLaps ELISA and the N-MID Osteocalcin ELISA were used for the 
quantitative measurement of CrossLaps and osteocalcin in sera. Bone mineral density was 
determined for the lumbar spines (L2-L4), proximal femur (neck), and forearm (the distal part) using 
dual-energy X-ray absorptiometry. 
Men had higher biochemical serum bone markers (P<0.0001). In women, there were progressive 
increases in serum CrossLaps after 30 years of age, peaking at >60 years. In men, serum 
CrossLaps levels were decreased progressively by increases in age, with the peak at 20 – 29 years. 
In women, there was a significant decrease in serum osteocalcin from 20 – 29 years to 30–49 years, 
followed by a progressive increases during 50 – 59 years, with the peak at >60 years. In men, the 
highest concentrations for serum osteocalcin occurred at 20 – 29 years. At all sites checked for 
bone mineral densitys, women in the high osteocalcin quartile had the lowest mean bone mineral 
densitys values, but women in the high CrossLaps quartile had the lowest mean bone mineral 
densitys at lumbar and radial sites. However, in men, bone mineral densitys values at neither site 
differed between the lowest and the highest quartiles of serum biochemical bone markers. 
We presented a five- year age-specific mean values of bone markers in a general healthy Iranian 
population. Only women in the high osteocalcin and CrossLaps quartiles had the lowest mean 
bone mineral densitys values at the lumbar and radial sites. Our results suggest that the 
significance of osteoclastic bone resorption or bone formation as a determinant of bone mineral 
densitys may depend on sex. 
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Introduction 
 
 arkers of bone turnover are 
becoming an important tool for 
practitioners in the management of 
osteoporosis. Changes in bone density can 
generally be seen after about two years of 
treatment,     whereas    biochemical   markers   can  
 
 
provide dynamic information about the 
effectiveness of therapeutic agents such as 
bisphosphonates, estrogens, selective estrogen 
receptor modulators (SERMS), and calcitonins 
within three to six months.1  
In addition, markers of bone turnover are 
expected to predict how much bone an individual 
will lose and how great a risk for fragility fractures 
they gain.2,3   
These potential uses may increase the 
prediction accuracy of bone densitometry and 
assist practitioners to successfully prevent 
osteoporosis or osteoporotic fractures in high- risk 
patients. Therefore, it is essential to establish a 
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reference database of the markers before using 
them in various clinical settings. The objectives of 
this study were firstly to find the age-specific value 
of serum CrossLaps (degradation products of C-
terminal telopeptides of type-1 collagen) which is a 
new biochemical marker of bone turnover and 
osteocalcin as a bone formation marker for a 
healthy Iranian population, and secondly to find 
the differences in bone mineral density (BMD) at 
various body sites between individuals with and 
without high biochemical markers of bone 
turnover. 
 
Materials and Methods 
 
Subjects 
This study was performed as a part of a larger 
epidemiologic study–the Iranian Multicenter 
Osteoporosis Study (IMOS)–where 6,000 normal 
subjects were randomly selected from five major 
cities throughout Iran. Details of the study can be 
found elsewhere.4 The study goal was to recruit 
120 healthy men and women, aged 20 – 69 years in 
each age decade in every center. The subjects of 
the present report were randomly selected from 13 
clusters in Bushehr Port, south of Iran.  
  
Measurements 
Bone mineral density was determined for 
lumbar spines (L2-L4), proximal femur (neck), and 
the distal forearm using dual-energy X-ray 
absorptiometry (DXA) (Osteocore II 
Osteodensitometer, Medilink, France). The 
accuracy of the measurements was proved by 
scanning phantoms and analyzing the scans.  
The serum CrossLaps ELISA (Nordic 
Bioscience Diagnostics A/S, Herlev, Denmark) 
was used for the quantification of degradation 
products of C-terminal telopeptides of type -1 
collagen in sera. The intra-assay coefficient of 
variations for low (0.242 ng/mL), medium (0.375 
ng/mL), and high (0.476 ng/mL) values were 
5.4%, 5.0%, and 5.1%, respectively.  
The N-MID® Osteocalcin ELISA (Nordic 
Bioscience Diagnostics A/S, Herlev, Denmark) 
was used for the quantitative measurement of 
osteocalcin in sera. The intra-assay coefficient of 
variations for low (7.0 ng/mL), medium (21.8 
ng/mL), and high (43.2 ng/mL) values were 3.4%, 
2.0%, and 2.4%, respectively.  
 
Statistics 
We found that log transformation of CrossLaps 
and osteocalcin gave a better fit to a Gaussian 
distribution. The 95%4 interval for CrossLaps and 
osteocalcin was defined as the arithmetic mean of 
the log-transformed data ±2 standard deviation 
(SD), raised to the power of 10.  
ANOVA was used to analyze the effects of 
bone biochemical marker quartiles on BMD at 
different body sites. The Bonferroni pairwise 
multiple comparisons test was used as the post hoc 
test to evaluate the differences in bone parameters 
between a single quartile and each of the other 
quartiles. Statistical analysis was performed by an 
IBM computer using the SPSS software version 




A total of 785 individuals (37% males, 63% 
females) were evaluated. Of the studied 
population, 137 (17.5%) were 20 – 29 years, 176 
(22.4%) were 30 – 39 years, 222 (28.3%) were 40 
– 49 years, 163 (20.8%) were 50 – 59 years, and 87 
(11.1%) were ≥60 years. Shown in Table 1 are the 
logarithmic means (and SD), as well as 95% 
confidence intervals for serum bone markers in the 
above age groups. Men had higher serum levels of 
biochemical bone markers (P<0.0001). 
CrossLaps showed a significant variation with 
age in both sexes (ANOVA, P<0.0001 for women 
and P=0.001 for men). In women, there were 
progressive increases in serum Crosslaps after the 
Table 1. Age- and sex-specific reference data for serum CrossLaps and osteocalcin in a healthy Iranian population. 
CrossLaps Osteocalcin 
Men Women Men Women  
Median 
ng/mL 












95% CI *  
ng/mL 
20 – 30 550 204 – 1548 310 109 – 912 15.98 5.01 – 41.68 12.44 4.89 – 28.18 
30 – 40 460 158 – 1318 260 100 – 691 11.96 5.24 – 27.54 8.11 3.46 – 19.95 
40 – 50 405 147 – 1122 240 87 – 870 11.30 4.57 – 23.98 8.93 2.88 – 26.30 
50 – 60 385 112 – 1348 420 123 – 1348 9.83 3.16 – 31.62 11.53 3.71 – 30.90 
>60 375 87 – 1148 470 144 – 1584 12.35 5.12 – 24.59 13.10 4.26 – 38.90 
Total 430 134 – 1348 297 100 – 1513 11.95 4.36 – 30.19 9.82 3.38 – 28.18 
*Confidence interval=arithmetic mean of log-transformed data (±SD), raised to the power of 10. 
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age of 30, peaking at >60 years. In men, serum 
CrossLaps levels were at their peak in the 20 – 29 
years age group, and decreased progressively with 
age.  
Osteocalcin also showed a significant variation 
with age in both sexes (ANOVA, P<0.0001). In 
women, there was a significant decrease in serum 
osteocalcin from 20 – 29 years to 30 – 49 years 
(P<0.0001). There were then progressive increases 
in serum osteocalcin from 50 – 59 years, peaking 
at >60 years (P<0.0001). In men, the highest 
concentrations for serum osteocalcin occurred at 
20 - 29 years (P<0.0001). 
In women, mean differences between the 
highest and lowest quartiles of osteocalcin were 
7.4% (P=0.004) for femoral neck BMD, 10.6% 
(P<0.00001) for radial BMD, and 7.4% (P 
<0.0001) for lumbar BMD, which shows that 
women in the highest quartile of osteocalcin had 
lower BMDs. These values for CrossLaps were 
5.5% (P=NS) for femoral neck BMD, 8.2% (P 
=0.02) for radial BMD, and 10.0% (P<0.0001) for 
lumbar BMD, which shows that women in the 
highest quartile of CrossLaps had lower BMDs at 
lumbar and radial sites. In men, however, analysis 
by quartiles of biochemical markers of bone 
turnover revealed no significant association with 




The present study established the reference 
values of two biochemical markers of bone 
turnover, serum CrossLaps and osteocalcin, in a 
group of healthy individuals of various ages. The 
subjects were randomly selected in an urban area 
to avoid sampling bias. Therefore, this population-
based database covering a wide range of ages 
would give the researchers the opportunity to make 
international or national comparisons of bone 
turnover markers.  
A steep elevation in the biochemical markers of 
bone turnover after menopause is widely accepted. 
Garnero et al.5 reported 37%, 52%, and 79% higher 
levels of osteocalcin, bone alkaline phosphatase, 
and CrossLaps, respectively in women <10 years 
after menopause compared to premenopausal 
women. The corresponding differences for 
CrossLaps and osteocalcin in the present study 
were 40% and 24%.  
The effects of aging on biochemical markers of 
bone turnover in men are poorly defined and are 
controversial. A fall in biochemical markers of 
bone turnover with age has been reported,6 while 
others have suggested that there is no change or an 
increase.7 We did not observe a uniform pattern for 
bone turnover markers in men.  
To evaluate the association between 
biochemical bone markers and BMD parameters, 
we compared average BMDs in both men and 
women, according to osteocalcin and CrossLaps 
quartiles. At all sites checked for BMD, women in 
the high osteocalcin quartile had the lowest mean 
BMD values but women in the high CrossLaps 
quartile had the lowest mean BMDs at lumbar and 
radial sites. One study also found a highly 
significant correlation between serum osteocalcin 
concentrations and BMD of the spine.8 Another 
report divided subjects into quartiles according to 
the urinary excretion of cross-linked N-
telopeptides (NTX) of type-1 collagen, a marker of 
bone resorption.9 There was an inverse relationship 
between the quartile of urinary NTX excretion and 
the mean BMD. These findings are consistent with 
the concept that osteoporosis is characterized by an 
increase in both bone formation and resorption.  
Despite these general trends, biochemical 
markers are not useful in making the diagnosis of 
osteoporosis because the values in normal subjects 
and patients with osteoporosis overlap 
substantially. In one report, for example, patients 
with low serum osteocalcin concentrations had 
bone densities that ranged from low to very high.1 
Using a population-based data set, it has been 
shown that none of the major biochemical markers 
of bone turnover provide sufficient diagnostic 
information useful for screening vertebral 
osteopenia or osteoporosis.10 
In men, most measurements of biochemical 
markers of bone turnover have been performed in 
small cohorts with limited age ranges, and results 
obtained in large cohorts are scanty. In elderly 
men, biochemical bone markers were negatively 
correlated with BMD.11 In the present study, BMD 
values at neither site in men differed between the 
lowest and highest quartiles of serum biochemical 
bone markers.  
Our results suggest that the significance of 
osteoclastic bone resorption or bone formation as a 
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